Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma

被引:11
|
作者
Miyazaki, Katsuki [1 ,2 ]
Morine, Yuji [2 ]
Xu, Caiming [1 ]
Nakasu, Chiharu [2 ]
Wada, Yuma [2 ]
Teraoku, Hiroki [2 ]
Yamada, Shinichiro [2 ]
Saito, Yu [2 ]
Ikemoto, Tetsuya [2 ]
Shimada, Mitsuo [2 ]
Goel, Ajay [1 ]
机构
[1] City Hope Comprehens Canc Ctr, Beckman Res Inst, Dept Mol Diagnost & Expt Therapeut, Duarte, CA 91010 USA
[2] Tokushima Univ, Dept Surg, Tokushima 7791510, Japan
关键词
Lenvatinib; Curcumin; EGFR; hepatocellular carcinoma; PI3K-AKT; resistance; ATEZOLIZUMAB PLUS BEVACIZUMAB; 1ST-LINE TREATMENT; NON-INFERIORITY; SORAFENIB; EFFICACY; CANCER; SAFETY;
D O I
10.3390/cells12040612
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Lenvatinib is a multi-kinase inhibitor approved as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). However, its response rate is unsatisfactory, primarily due to the acquisition of resistance, which limits its clinical significance for treating patients with HCC. Recent evidence suggests that epidermal growth factor receptor (EGFR) activation can trigger Lenvatinib-resistance; and is considered an important therapeutic target in HCC. Curcumin, one of the most studied naturally occurring botanicals with robust anti-cancer activity, is also reported to be a potent tyrosine kinase inhibitor. In this study, we hypothesized that the anti-EGFR potential of Curcumin might help overcome Lenvatinib resistance in HCC. We established two Lenvatinib-resistant cells and discovered that a combination of Curcumin and Lenvatinib exhibited a synergistic anti-tumor efficacy in the resistant HCC cell lines. In line with previous reports, Lenvatinib-resistant cell lines revealed significant activation of the EGFR, and genomewide transcriptomic profiling analysis identified that the PI3K-AKT pathway was associated with Lenvatinib resistance. The combination treatment with Curcumin and Lenvatinib dramatically suppressed gene and protein expression of the EGFR-PI3K-AKT pathway, suggesting Curcumin overcomes Lenvatinib resistance via inhibition of EGFR. We further validated these findings in tumor spheroids derived from resistant cell lines. In conclusion, we, for the first time, report that Curcumin reverses Lenvatinib resistance in HCC, and that their combination has clinical application potential for adjunctive treatment in HCC.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Reversal of lenvatinib resistance by curcumin via EGFR signaling pathway in hepatocellular carcinoma
    Miyazaki, Katsuki
    Morine, Yuji
    Xu, Caiming
    Shimada, Mitsuo
    Goel, Ajay
    CANCER RESEARCH, 2023, 83 (07)
  • [2] EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
    Xiaoping He
    Yohko Hikiba
    Yoshimasa Suzuki
    Yoshinori Nakamori
    Yushi Kanemaru
    Makoto Sugimori
    Takeshi Sato
    Akito Nozaki
    Makoto Chuma
    Shin Maeda
    Scientific Reports, 12
  • [3] EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
    He, Xiaoping
    Hikiba, Yohko
    Suzuki, Yoshimasa
    Nakamori, Yoshinori
    Kanemaru, Yushi
    Sugimori, Makoto
    Sato, Takeshi
    Nozaki, Akito
    Chuma, Makoto
    Maeda, Shin
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [4] EGFR inhibition may overcome the resistance to lenvatinib in hepatocellular carcinoma cells
    He, Xiaoping
    Maeda, Shin
    CANCER SCIENCE, 2022, 113 : 427 - 427
  • [5] Resistance of Lenvatinib in Hepatocellular Carcinoma
    Guo, Jinhui
    Zhao, Junjun
    Xu, Qiuran
    Huang, Dongsheng
    CURRENT CANCER DRUG TARGETS, 2022, 22 (11) : 865 - 878
  • [6] Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma
    Hu, Beiyuan
    Zou, Tiantian
    Qin, Wei
    Shen, Xiaotian
    Su, Yinghan
    Li, Jianhua
    Chen, Yang
    Zhang, Ze
    Sun, Haoting
    Zheng, Yan
    Wang, Chao-Qun
    Wang, Zhengxin
    Li, Tian-En
    Wang, Shun
    Zhu, Le
    Wang, Xufeng
    Fu, Yan
    Ren, Xudong
    Dong, Qiongzhu
    Qin, Lun-Xiu
    CANCER RESEARCH, 2022, 82 (20) : 3845 - 3857
  • [7] Effects of Curcumin-mediated Photodynamic Therapy on Notch Signaling Pathway in a Rat Model of Cervical Cancer
    LIU Hong-lian
    LIU Zhao-sheng
    Chinese Journal of Biomedical Engineering, 2024, 33 (03) : 122 - 130
  • [8] EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma
    Lim, Mir
    Franses, Joseph W.
    Imperial, Robin
    Majeed, Umair
    Tsai, Jill
    Hsiehchen, David
    GASTROENTEROLOGY, 2023, 164 (06) : 1006 - +
  • [9] Modeling therapy resistance via the EGFR signaling pathway
    Plattner, Christina
    Hackl, Hubert
    FEBS JOURNAL, 2019, 286 (07) : 1284 - 1286
  • [10] FBXO32 ubiquitination of SUFU promotes progression and lenvatinib resistance in hepatocellular carcinoma via hedgehog signaling
    Shunyi Wang
    Rui Peng
    Chen Chen
    Daoyuan Tu
    Jun Cao
    Bingbing Su
    Songsong Fan
    Yangyang Miao
    Chi Zhang
    Guoqing Jiang
    Shengjie Jin
    Dousheng Bai
    Medical Oncology, 42 (4)